Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 9/30/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $9,423 | $11,225 | $46,910 | $48,382 |
| - Cash | $74 | $41 | $70 | $76 |
| + Debt | $0 | $0 | $750 | $11 |
| Enterprise Value | $9,349 | $11,184 | $47,590 | $48,317 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EBITDA | -$771 | -$653 | -$5,272 | -$1,011 |
| % Margin | – | – | – | – |
| Net Income | -$857 | -$716 | -$5,311 | -$1,036 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.009 | -0.008 | -0.057 | -0.011 |
| % Growth | -18.2% | 86.4% | -407.1% | – |
| Operating Cash Flow | -$717 | – | -$897 | -$1,270 |
| Capital Expenditures | $0 | – | $0 | -$0 |
| Free Cash Flow | -$717 | – | -$897 | -$1,270 |